ReviewMolecular diagnosis & therapy2021
Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression.
Review in Molecular diagnosis & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- miR-224-5p alleviates oxygen-glucose deprivation/reperfusion injury via regulating FAS.Journal of thrombosis and thrombolysis · 2026Article
- Multi-omic Profiling of Recurrence Risk Across Breast Cancer Subtypes.medRxiv : the preprint server for health sciences · 2026Article
- Review
- Transcriptional modulation of the PI3K/AKT/mTOR signaling pathway mediated by HPV16Exploration of targeted anti-tumor therapy · 2026Article
- Pan-immune-inflammation value: racial variations and differences in prognostic accuracy across breast cancer subtypes at a single institution.Frontiers in oncology · 2026Article
- Whole-exome sequencing of FFPE samples reveals mutations associated with Luminal A breast cancer recurrence.BMC biotechnology · 2025Article
- Prognostic impact of ER-staining patterns and heterogeneity of ER positive HER2 negative breast cancer.Breast cancer (Tokyo, Japan) · 2025Article
- Analyzing the Gaps in Breast Cancer Diagnostics in Poland-A Retrospective Observational Study in the Data Donation Model.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Estrogen receptor alpha dynamics and plasticity during endocrine resistance.Biology direct · 2025Article
- Investigation of circulating miR-182-3p, miR -382-3p and miR -93, miR -142-3p involved in tamoxifen resistance and sensitivity in luminal-subtype breast cancer patients: a case-control study.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Intratumoral and peritumoral radiomics signature based on DCE-MRI can distinguish between luminal and non-luminal breast cancer molecular subtypes.Scientific reports · 2025Article
- From Breast to Eye: A Rare Case of Ocular Metastasis From Luminal Breast Cancer in a Nicaraguan Patient.Cureus · 2025Article
- Article
- Therapeutic Potential of Underexplored Phytoconstituents Targeting Molecular Pathways in Breast Cancer Subtypes.Mini reviews in medicinal chemistry · 2025Review
- Application of DCE-MRI radiomics and heterogeneity analysis in predicting luminal and non-luminal subtypes of breast cancer.Frontiers in oncology · 2025Article
- Tumor Immune Response as a Biomarker for Metastasis-Free Survival of Breast Cancer and Immune Checkpoint Inhibition Therapy: A Retrospective Cohort Study.Breast cancer : basic and clinical research · 2025Article
- The expression of epidermal growth factor receptor 2 and its relationship with tumor-infiltrating lymphocytes and clinical pathological features in breast cancer patients.Open life sciences · 2025Article
- Histogram analysis comparison of readout-segmented and single-shot echo-planar imaging for differentiating luminal from non-luminal breast cancer.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hormone-receptor positive (HR+) breast cancer (BC) (including the luminal A and the luminal B subtypes) is the most common type of tumor in women diagnosed with early-stage BC (EBC). It represents a highly heterogeneous subgroup that is characterized by different risks of relapse. The aim of this review is to discuss the possible role played by the immune response in predicting this risk, along with the most common clinical and pathological factors and molecular tools that have been developed and are already in use. As opposed to what has previously been observed in the most aggressive human epidermal growth factor receptor 2 (HER2)-positive and triple-negative breast cancer (TNBC) subtypes, a high proportion of tumor-infiltrating lymphocytes (TILs)-reflecting a spontaneous and pre-existing immune response to the tumor-has been linked to a worse prognosis in HR+ EBC. This work provides some immune biological rationale explaining these findings and provides the basics to understand the principal clinical trials that are testing immunotherapy in HR+ (luminal) BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.